

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Timolol / Dorzolamide Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Pharmaceutical

Recommended restrictions  
on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
120 Moorgate  
EC2M 6UR London, United Kingdom

Telephone : +44 (0) 2081548000

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

**Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

Specific target organ toxicity - repeated exposure, Category 1, Cardio-vascular system, Central nervous system, Gastro-intestinal tract, Lungs

H372: Causes damage to organs through prolonged or repeated exposure.

#### 2.2 Label elements

**Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version 3.5      Revision Date: 14.04.2025      SDS Number: 9371429-00009      Date of last issue: 28.09.2024  
Date of first issue: 27.08.2021

Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H372 Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.
Precautionary statements	:	<b>Prevention:</b> P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. <b>Response:</b> P314 Get medical advice/ attention if you feel unwell.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Dorzolamide	130693-82-2	Acute Tox. 4; H302 STOT RE 2; H373 (Central nervous system, Gastrointestinal tract, Bone, Blood, Bladder)	$\geq 1 - < 10$
(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate	26921-17-5 248-111-5	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Lungs, Cardio-vascular system)	$\geq 0.1 - < 1$

For explanation of abbreviations see section 16.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- |                            |   |   |
|----------------------------|---|---|
| General advice             | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.  |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).   |
| If inhaled                 | : | If inhaled, remove to fresh air.<br>Get medical attention.  |
| In case of skin contact    | : | In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact     | : | Flush eyes with water as a precaution.<br>Get medical attention if irritation develops and persists.  |
| If swallowed               | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.   |

#### 4.2 Most important symptoms and effects, both acute and delayed

- |       |   |   |
|-------|---|---|
| Risks | : | Causes damage to organs through prolonged or repeated exposure. |
|-------|---|---|

#### 4.3 Indication of any immediate medical attention and special treatment needed

- |           |   |   |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- |                                |   |  |
|--------------------------------|---|--|
| Suitable extinguishing media   | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical |
| Unsuitable extinguishing media | : | None known.  |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Sulphur oxides  
Hydrogen chloride

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |  |
|-------------------------|---|--|
| Technical measures      | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  |
| Local/Total ventilation | : | Use only with adequate ventilation.  |
| Advice on safe handling | : | Do not breathe the mist or vapours.<br>Do not swallow.<br>Avoid contact with eyes.<br>Avoid prolonged or repeated contact with skin.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment.   |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |  |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store in accordance with the particular national regulations.  |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents<br>Self-reactive substances and mixtures<br>Organic peroxides<br>Explosives<br>Gases |

### 7.3 Specific end use(s)

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
------------	---------	------------------	--------------------	-------

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version 3.5      Revision Date: 14.04.2025      SDS Number: 9371429-00009      Date of last issue: 28.09.2024  
Date of first issue: 27.08.2021

		of exposure)		
Dorzolamide	130693-82-2	TWA	10 µg/m3 (OEB 3)	Internal
	Further information: Eye			
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal
(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate	26921-17-5	TWA	10 µg/m3 (OEB 3)	Internal
	Further information: Eye, Skin			
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

### 8.2 Exposure controls

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to BS EN 143

Filter type : Particulates type (P)

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Appearance	: liquid
Colour	: colourless
Odour	: No data available
Odour Threshold	: No data available
pH	: 5.6
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: 1.02
Density	: No data available
Solubility(ies)	
Water solubility	: soluble
Partition coefficient: n-octanol/water	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

---

### 9.2 Other information

Molecular weight : No data available

Particle size : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

#### Components:

##### Dorzolamide:

Acute oral toxicity : LD50 (Rat): 1,927 mg/kg  
LD50 (Mouse): 1,320 mg/kg



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg

LD50 (Mouse): 1,140 mg/kg

Acute toxicity (other routes of administration) : LD50 (Mouse): 300 mg/kg  
Application Route: Intraperitoneal

LD50 (Mouse): 800 mg/kg  
Application Route: Subcutaneous

### **Skin corrosion/irritation**

Not classified based on available information.

### **Components:**

### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

### **Serious eye damage/eye irritation**

Not classified based on available information.

### **Components:**

### **Dorzolamide:**

Species : Monkey  
Result : Mild eye irritation

### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Species : Rabbit  
Result : Mild eye irritation

Species : Dog  
Result : No eye irritation

### **Respiratory or skin sensitisation**

### **Skin sensitisation**

Not classified based on available information.

### **Respiratory sensitisation**

Not classified based on available information.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

---

### Components:

#### **Dorzolamide:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: Weak sensitizer

#### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Dorzolamide:**

Genotoxicity in vitro	: Test Type: Chromosomal aberration Result: negative  Test Type: Alkaline elution assay Test system: rat hepatocytes Result: negative  Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster fibroblasts Result: negative  Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Cytogenetic assay Species: Mouse Result: negative

#### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative
Genotoxicity in vivo	: Test Type: In vivo micronucleus test Species: Mouse Method: OECD Test Guideline 474 Result: negative

#### **Carcinogenicity**

Not classified based on available information.

### Components:

#### **Dorzolamide:**

Species	: Rat, male
Application Route	: Oral
Exposure time	: 2 Years : 20 mg/kg body weight

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

Result : negative  
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Mouse  
Application Route : Oral  
Exposure time : 21 month(s)  
Result : negative

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
LOAEL : 300 mg/kg body weight  
Result : negative  
Target Organs : Adrenal gland  
Remarks : The significance of these findings for humans is not certain.

Species : Mouse, female  
Application Route : Oral  
Exposure time : 18 Months  
LOAEL : 500 mg/kg body weight  
Result : negative  
Target Organs : Lungs, Mammary gland, Uterus (including cervix)  
Remarks : The significance of these findings for humans is not certain.

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Dorzolamide:

Effects on fertility : Test Type: Fertility  
Species: Rat, male and female  
Application Route: Oral  
Fertility: NOAEL: 7.5 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 1 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

Result: Embryotoxic effects and adverse effects on the off-spring were detected only at high maternally toxic doses

### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

- |                                    |   |
|------------------------------------|---|
| Effects on fertility               | : Test Type: Fertility/early embryonic development<br>Species: Rat<br>Application Route: Oral<br>Fertility: NOAEL Mating/Fertility: 150 mg/kg body weight<br>Early Embryonic Development: NOAEL F1: 150 mg/kg body weight |
| Effects on foetal development      | : Test Type: Embryo-foetal development<br>Species: Rabbit<br>Developmental Toxicity: LOAEL F1: 50 mg/kg body weight<br>Result: Some evidence of adverse effects on development, based on animal experiments.              |
| Reproductive toxicity - Assessment | : Some evidence of adverse effects on development, based on animal experiments.   |

### **STOT - single exposure**

Not classified based on available information.

### **STOT - repeated exposure**

Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.

#### **Product:**

- |               |   |
|---------------|---|
| Target Organs | : Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs |
| Assessment    | : Causes damage to organs through prolonged or repeated exposure.               |

#### **Components:**

##### **Dorzolamide:**

- |               |  |
|---------------|--|
| Target Organs | : Central nervous system, Gastrointestinal tract, Bone, Blood, Bladder |
| Assessment    | : May cause damage to organs through prolonged or repeated exposure.   |

### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

- |               |   |
|---------------|---|
| Target Organs | : Lungs, Cardio-vascular system                                   |
| Assessment    | : Causes damage to organs through prolonged or repeated exposure. |

### **Repeated dose toxicity**

#### **Components:**

##### **Dorzolamide:**

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

Species	: Rat
NOAEL	: 0.05 mg/kg
Application Route	: Oral
Target Organs	: Bladder, Kidney

Species	: Dog
NOAEL	: 0.05 mg/kg
LOAEL	: 2 mg/kg
Application Route	: Oral
Exposure time	: 1 yr
Target Organs	: Gastrointestinal tract, Bone, Blood

Species	: Monkey
NOAEL	: 0.05 mg/kg
Exposure time	: 1 yr
Target Organs	: Gastrointestinal tract, Bone, Blood

### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Species	: Rat
NOAEL	: 25 mg/kg
Application Route	: Oral
Exposure time	: 67 Weeks

Species	: Dog
NOAEL	: 10 mg/kg
Application Route	: Oral
Exposure time	: 54 Weeks
Target Organs	: Kidney

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

#### **Product:**

Eye contact	: Symptoms: The most common side effects are:, bitter taste, burning or stinging of the eye, Blurred vision, Abdominal pain, Dizziness, digestive disorder, eye pain, Headache, hypertension, Nausea, upper respiratory tract infection
-------------	---

#### **Components:**

##### **Dorzolamide:**

Eye contact	: Symptoms: burning or stinging of the eye, Blurred vision, tearing, asthenia, bitter taste, Nausea, dry mouth, Headache
-------------	--

##### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Eye contact	: Symptoms: burning or stinging of the eye, dryness of the eyes, Headache, Nausea, Dizziness, dry mouth, changes in libido, hair loss, Allergic reactions
Ingestion	: Symptoms: Headache, Fatigue, Respiratory disorders, Gastrointestinal discomfort, Allergic reactions, Rash, hair loss, altered mental status, Dizziness, changes in libido

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

### SECTION 12: Ecological information

#### 12.1 Toxicity

##### Components:

##### **Dorzolamide:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 699 mg/l Exposure time: 48 h
Toxicity to microorganisms	:	EC50 (Natural microorganism): > 800 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

##### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 411 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 161 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to microorganisms	:	EC50 : > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition  EC50 (Photobacterium phosphoreum): > 1,800 mg/l

#### 12.2 Persistence and degradability

##### Components:

##### **Dorzolamide:**

Biodegradability	:	Result: not rapidly degradable Biodegradation: 5 % Exposure time: 28 d Method: OECD Test Guideline 314
------------------	---	---

##### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 0 % Exposure time: 30 d
Stability in water	:	Hydrolysis: 0 %(61 d) Method: FDA 3.09

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

### 12.3 Bioaccumulative potential

#### Components:

##### **Dorzolamide:**

Partition coefficient: n-octanol/water : log Pow: 0.292

##### **(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Partition coefficient: n-octanol/water : log Pow: 1.48

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

#### Product:

Endocrine disrupting potential : This substance/mixture does not contain components considered to have endocrine disrupting properties for environment according to UK REACH Article 57(f).

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14: Transport information

### 14.1 UN number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

**IMDG** : Not regulated as a dangerous good

**IATA** : Not regulated as a dangerous good

### 14.2 UN proper shipping name

**ADN** : Not regulated as a dangerous good

**ADR** : Not regulated as a dangerous good

**RID** : Not regulated as a dangerous good

**IMDG** : Not regulated as a dangerous good

**IATA** : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

**ADN** : Not regulated as a dangerous good

**ADR** : Not regulated as a dangerous good

**RID** : Not regulated as a dangerous good

**IMDG** : Not regulated as a dangerous good

**IATA** : Not regulated as a dangerous good

### 14.4 Packing group

**ADN** : Not regulated as a dangerous good

**ADR** : Not regulated as a dangerous good

**RID** : Not regulated as a dangerous good

**IMDG** : Not regulated as a dangerous good

**IATA (Cargo)** : Not regulated as a dangerous good

**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) : Conditions of restriction for the following entries should be considered:  
Number on list 3



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	: Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain)	: Not applicable
Regulation (EU) No 2024/590 on substances that deplete the ozone layer	: Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	: Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	: Not applicable
Control of Major Accident Hazards Regulations 2015 (COMAH)	: Not applicable

### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

### The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information	: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	--

### Full text of H-Statements

H302	: Harmful if swallowed.
H361d	: Suspected of damaging the unborn child.
H372	: Causes damage to organs through prolonged or repeated

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

H373 : exposure.  
: May cause damage to organs through prolonged or repeated exposure.

### Full text of other abbreviations

Acute Tox. : Acute toxicity  
Repr. : Reproductive toxicity  
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

STOT RE 1 H372

### Classification procedure:

Based on product data or assessment

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Timolol / Dorzolamide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.5	14.04.2025	9371429-00009	Date of first issue: 27.08.2021

---

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN